Last 12 months
Inside the activity.
1 purchase rows · 45 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 3 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 36 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2016 Filed May 10, 2017 00:57 UTC |
Freund Charles RichardEVP Global Sales
|
GrantCommon Stock | 1,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031126 · doc4.xml · nonDerivative · entry 1 Freund Charles Richard · CIK 0001516339 · EVP Global Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: Vesting of performance based restricted stock Read SEC document |
| October 21, 2015 Filed Apr 7, 2017 20:38 UTC |
Gavrilenya AlexeyPresident East/Central Europe
|
GrantStock Options · Derivative | 15,000 | $0.00 Strike: $144.59 | $0.00 |
DisclosureSEC source: 0001209191-17-026273 · doc4.xml · derivative · entry 1 Gavrilenya Alexey · CIK 0001654829 · President East/Central Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-10-21 F1 · security: Options vest 0% in 2017 and then ratably (50%) on each of October 21, 2017 and 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.